The mixed Phase 2b SLE data creates a binary overhang: the IFNGS-high subgroup signal supports a path to Phase 3, but the overall trial miss and high placebo response raise execution risk. The stock will likely trade on the perceived probability of regulatory acceptance for a Phase 3 program in the IFNGS-high population. The maintained Q4 2026 psoriasis NDA timeline provides a floor of support. Monitor for End of Phase 2 meeting outcomes and any partnering discussions.
Price Chart
Executive Summary
Alumis reported topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe SLE. The trial did not meet its primary endpoint (BICLA) or key secondary endpoints in the overall population, with a higher-than-expected proportion of IFNGS-low patients (40%) driving a high placebo response. However, robust, dose-dependent responses were observed in the prespecified IFNGS-high subgroup (e.g., BICLA response rate 52.6% for 40mg BID vs 28.6% placebo), and the drug was well-tolerated with no new safety signals. The company plans to engage regulators on Phase 3 development in the IFNGS-high population and remains on track to file an NDA for envudeucitinib in plaque psoriasis in Q4 2026.
Key Facts
- Phase 2b LUMUS trial (N=408) of envudeucitinib in SLE did not meet primary endpoint (BICLA) or key secondary endpoints in the overall trial population.
- In the prespecified IFNGS-high subgroup (62% of patients), envudeucitinib showed robust, dose-dependent responses: BICLA response rate 52.6% (40mg BID) vs 28.6% placebo; SRI-4 response rate 60.9% (40mg BID) vs 33.1% placebo.
- The trial had an unexpectedly high proportion of IFNGS-low patients (40%), which drove a high placebo response and reduced overall efficacy signals.
- Envudeucitinib was generally well-tolerated with no new safety signals; no MACE, extended MACE, or malignancies reported.
- Alumis plans End of Phase 2 meetings with FDA and EMA to discuss Phase 3 design in the IFNGS-high SLE population.
- Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.
Financial Impact
No financial figures reported in the filing. The $2.8B market cap company's SLE program faces a binary regulatory path forward, while the psoriasis NDA filing timeline is maintained.
Risk Factors
- Regulatory agencies may not accept the IFNGS-high subgroup analysis as sufficient to support Phase 3 development, requiring additional Phase 2 data.
- The high placebo response rate and unexpected IFNGS-low patient distribution could complicate future trial design and enrollment.
- Failure to replicate the IFNGS-high subgroup results in a larger Phase 3 trial would significantly impair the SLE program's value.
- Execution risk on the psoriasis NDA filing timeline and subsequent approval.
- Potential need for additional capital to fund Phase 3 SLE development and ongoing operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-104145 |
| Document: tm2624540d1_8k.htm | 0001104659-26-104145 |
| Document: tm2624540d1_ex99-1.htm | 0001104659-26-104145 |
| Document: 0001104659-26-104145-index-headers.html | 0001104659-26-104145 |
| Document: 0001104659-26-104145-index.html | 0001104659-26-104145 |
| Document: 0001104659-26-104145.txt | 0001104659-26-104145 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | Insider Buy | $9.90 $9.18 | ▼ −7.27% | ▼ −8.13% | $6.51 (−34.24%) |
Sep 1, 2026 7w ago | 8-K | $9.47 $10.35 | ▲ +9.29% | ▲ +8.85% | $6.51 (−31.26%) |
Aug 15, 2026 10w ago | Institutional Cluster | $25.50 $24.88 | ▼ −2.43% | ▼ −1.76% | $6.51 (−74.47%) |
Aug 10, 2026 11w ago | 8-K | $25.37 $25.55 | ▲ +0.71% | ▲ +0.46% | $6.51 (−74.34%) |
Aug 5, 2026 11w ago | Insider Cluster | $27.80 $27.60 | ▼ −0.72% | ▼ −1.33% | $6.51 (−76.58%) |
Aug 5, 2026 11w ago | Insider Cluster | $27.80 $27.60 | ▼ −0.72% | ▼ −1.33% | $6.51 (−76.58%) |
Jun 29, 2026 17w ago | 8-K | $27.14 $28.14 | ▲ +3.68% | ▲ +2.91% | $6.51 (−76.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $20.90 $24.15 | ▲ +15.55% | ▲ +15.01% | $6.51 (−68.85%) |
May 18, 2026 23w ago | DEFA14A | $21.53 $22.04 | ▲ +2.39% | ▲ +1.35% | $6.51 (−69.76%) |
Mar 28, 2026 30w ago | Press Release | $20.21 $22.03 | ▲ +9.01% | ▲ +6.11% | $6.51 (−67.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers